 The results of this study suggest that the use of Betalovumab, BEB, monoclonal antibody, MAB, does not appear to provide any significant benefit in reducing the risk of hospitalization and or death within 30 days among patients with severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, Omicron subvariant infections in the Banner healthcare system in the southwestern United States. This article was authored by Shreelika Sridhara, Amit B. Gungar, Halil K. Errol and others.